Next‐generation sequencing‐defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse
- 23 May 2019
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 94 (8) , 902-912
Abstract
In acute myeloid leukemia (AML), the assessment of post‐treatment minimal residual disease (MRD) may inform a more effective management approach. We investigated the prognostic utility of next‐generation sequencing (NGS)‐based MRD detection undertaken before hematopoietic stem cell transplantation (HSCT). Forty‐two AML subjects underwent serial disease monitoring both by standard methods, and a targeted 42‐gene NGS assay, able to detect leukemia‐specific mutant alleles (with >0.5% VAF) (mean 5.1 samples per subject). The prognostic relevance of any persisting diagnostic mutation before transplant (≤27 days) was assessed during 22.1 months (median) of post‐transplant follow‐up. The sensitivity of the NGS assay (27 MRD‐positive subjects) exceeded that of the non‐molecular methods (morphology, FISH, and flow cytometry) (11 positive subjects). Only one of the 13 subjects who relapsed after HSCT was NGS MRD‐negative (92% assay sensitivity). The cumulative incidence of post‐transplant leukemic relapse was significantly higher in the pre‐transplant NGS MRD‐positive (vs MRD‐negative) subjects (P = .014). After adjusting for TP53 mutation and transplant conditioning regimen, NGS MRD‐positivity retained independent prognostic significance for leukemic relapse (subdistribution hazard ratio = 7.3; P = .05). The pre‐transplant NGS MRD‐positive subjects also had significantly shortened progression‐free survival (P = .038), and marginally shortened overall survival (P = .068). In patients with AML undergoing HSCT, the pre‐transplant persistence of NGS‐defined MRD imparts a significant, sensitive, strong, and independent increased risk for subsequent leukemic relapse and death. Given that NGS can simultaneously detect multiple leukemia‐associated mutations, it can be used in the majority of AML patients to monitor disease burdens and inform treatment decisions.Keywords
This publication has 45 references indexed in Scilit:
- Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AMLBlood, 2018
- Next-generation sequencing–based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapseBlood, 2018
- Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AMLTransplantation and Cellular Therapy, 2018
- Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2018
- Molecular Minimal Residual Disease in Acute Myeloid LeukemiaNew England Journal of Medicine, 2018
- Measurable residual disease testing in acute myeloid leukaemiaLeukemia, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study GroupTransplantation and Cellular Therapy, 2015
- The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approachNature Reviews Clinical Oncology, 2012
- Assignment of scores for the hematopoietic cell transplantation comorbidity index: integer vs exact weightsBone Marrow Transplantation, 2010